Author Archives: No Author

 The placebo effect’s impact on drug development is widely known, but you may be surprised to learn that the word “placebo” has had multiple meanings — all of them pejorative — going back hundreds of years. Scott Millard, Premier Research’s Executive Director for Strategic Development and Analgesia, explores the role of placebos in theRead more

 Patient registries and natural history studies are vital tools for orphan drug researchers, who often struggle with limited understanding of diseases and sparse data due to small patient numbers. In the second installment of the Premier Voices podcast with Angi Robinson, Vice President, Clinical Development Services, Rare Disease & Pediatrics, and Juliet Moritz, ViceRead more

The inaugural edition of Premier Voices focuses on rare oncology drug development and takes a looks at: * Using adaptive design to limit patient exposure to ineffective treatments and increase the overall likelihood of success * Making the most of small and geographically dispersed patient populations * Dealing with limitations such as a lack of definedRead more

DURHAM, N.C., July 2, 2018 — Premier Research’s head of patient engagement will talk about the role of natural history studies in clinical research at the International Children’s Advisory Network’s Research & Advocacy Summit on July 12 in Edinburgh, U.K. Juliet Moritz, the CRO’s Executive Director, Program Strategy, Rare Disease and Pediatrics/Patient Engagement, will discussRead more

Premier Research recently contributed to the STARR 911 initiative, a project of the STARR Coalition to provide actionable guidance for clinical researchers after identifying volunteers with suicidal leanings. This post provides more information on the process itself, which was presented earlier this year at the 2018 ASCP Annual Meeting in Miami. Background The primary goalRead more

Having a chronic condition increases the odds of suicide by 363%, and patients with mental illness are particularly at risk.[1] For individuals contacting sites about possible enrollment in a clinical trial, the call may be their first attempt to reach out for help – yet many do not receive the education and support that couldRead more

It’s been 46 years since researchers Theodore Friedmann and Richard Roblin published a landmark paper in the journal Science that posed a provocative question: “Gene therapy for human genetic disease?” And while clinical trials for gene therapy drugs have become much more common in the past 20 years — more than 2,400 had been conductedRead more

You get one chance to initiate a clinical trial. Botch the start-up and you’ll expend great effort correcting course and playing catch-up. The waste of money and time — commodities that are chronically scarce among the biotech and specialty pharma companies that comprise most of our customer base — can be devastating. That’s why weRead more

This weekend, just in time for ASCO’s annual meeting in Chicago, we’re launching our new podcast, Premier Voices! Hosted by our own Paul Mirek, marketing manager at Premier, the podcast is aimed at sharing viewpoints and insights of our clinical research experts around the network and beyond. It’s our chance to get inside their headsRead more

Between navigating relatively uncharted territory and the practical limitations of most gene therapy delivery systems, ensuring successful clinical trials of these products is a serious challenge for even the most experienced researchers. Compounding this is the long-term nature of most gene therapy trials — it’s not unusual to have follow-up periods of a decade or more.Read more

Phone Us Now
Email Us Now